Crossmark

Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer

Crossref DOI link: https://doi.org/10.1007/s10637-016-0335-x

Published Online: 2016-03-21

Published Print: 2016-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kummar, Shivaani

Wade, James L.

Oza, Amit M.

Sullivan, Daniel

Chen, Alice P.

Gandara, David R.

Ji, Jiuping

Kinders, Robert J.

Wang, Lihua

Allen, Deborah

Coyne, Geraldine O’Sullivan

Steinberg, Seth M.

Doroshow, James H.
Funding

Funding for this research was provided by:

National Cancer Institute (HHSN261200800001E, HHSN261200800001E)
License Information

Text and Data Mining valid from 2016-03-21

Version of Record valid from 2016-03-21
More Information

Article History

Received: 10 February 2016

Accepted: 26 February 2016

First Online: 21 March 2016

Compliance with ethical standards

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below